Diabetes

What can CGM's provide for individuals who don't have diabetes?

Insulet plans to commercialize the new product in the United States starting in 2024.

The MiniMed 780G has been available in Europe since 2020.

Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?

Pharmacists can provide support and guidance to patients during their month of fasting.

According to a recent study, the diabetes medication semaglutide is more effective as a 25 mg or 50 mg dose on its own, rather than a 14 mg add-on dose with other medications.

Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.

About 1 in 10 individuals in the United States have diabetes. A recent study examines how much they are paying on average for access to treatment for the common disease.

The company also will establish a $35 out-of-pocket price cap for for all patients with commercial insurance that use Latnus

Significant differences in the use of insulin pump and/or CGM technology were noted based on demographic and socioeconomic factors

Leading health organizations are urging those with diabetes and other chronic conditions to get the influenza vaccine.

Not only were people with newly diagnosed type 2 diabetes less likely to develop dementia if they took pioglitazone, but the benefit was stronger among patients with a history of ischemic heart disease or stroke.

Two studies found digital therapeutics can help patients manage their type 2 diabetes effectively regardless of race or ethnicity.

A smartphone app is associated with improvement in HbA1c levels, but physician involvement with patients and other factors may be the benefit.

Pharmaceutical companies are experiencing supply chain disruptions and shortages because of the popularity of diabetes drugs used for weight loss.

Results of a phase 3 clinical trial represent another avenue of treatment for children and adolescents living with type 2 diabetes.

According to the study, vitamin D was beneficial in decreasing the risk for diabetes and increasing the rate of regression back to normal glucose regulation.

Mallya can provide convenience for insulin pen users; however, it has yet to be released in the United States.

The new medication reduces HbA1c and improves glycemic control as an adjunct to diet and exercise.

Pharmaceutical makers, price managers out of control with ‘necessary drug’ for millions, Attorney General says.

The American Diabetes Association has updated their Standards of Care, which includes new hypertension guidelines, medication guidance, and emphasis on weight loss.

Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.

The program Project Power helps give children and their families the tools to reduce disparities found with diabetes.

The Medicare Part D Senior Savings Model — a CMS effort to test $35 copays for insulin — led to lowered total costs for beneficiaries.